861
Participants
Start Date
May 29, 2018
Primary Completion Date
January 27, 2021
Study Completion Date
December 14, 2023
177Lu-PSMA-617
Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles. After 4 cycles, patients were assessed for (1) evidence of response, (2) residual disease, and (3) tolerance to 177Lu-PSMA-617. If all 3 assessments were met the patient might received an additional 2 cycles of 177Lu-PSMA-617.
Best supportive/best standard of care
Best supportive/best standard of care as defined by the local investigator
Memorial Sloan Kettering Cancer Center, New York
New York Presbyterian Hospital/Weill Cornell Medical Center, New York
Pennsylvania Cancer Specialists & Research Institute, Gettysburg
Thomas Jefferson University Hospital, Philadelphia
Washington DC VA Medical Center, Nuclear Medicine Service, Washington D.C.
University of Maryland Greenebaum Cancer Center, Baltimore
Chesapeake Urology Associates (CUA) P.A., Towson
Emily Couric Clinical Cancer Center, Charlottesville
Duke University Medical Center, Duke Cancer Center, Durham
Carolina Urologic Research Center, Myrtle Beach
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Norton Cancer Institute, Louisville
Greater Dayton Cancer Center, Kettering
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Parkview Research Center, Fort Wayne
VA Ann Arbor Healthcare System, Ann Arbor
University of Michigan Hospitals, Ann Arbor
Karmanos Cancer Center, Detroit
University of Iowa Hospitals and Clinics, Iowa City
Iowa City VA Medical Center, Iowa City
Mayo Clinic - Rochester, Rochester
Northwestern University, Chicago
Saint Louis University Hospital, St Louis
VA St. Louis Health Care System - John Cochran, St Louis
XCancer Omaha / Urology Cancer Center, Omaha
Tulane Medical Center, Tulane Cancer Center, New Orleans
VA North Texas Health Care System, Nuclear Medicine Service, Dallas
UT Southwestern Medical Center, Dallas
Excel Diagnostics & Nuclear Oncology Center, Houston
University of Colorado Hospital, Aurora
HonorHealth Research Institute, Scottsdale
New Mexico Oncology Hematology Consultants Ltd., New Mexico Cancer Center, Albuquerque
Comprehensive Cancer Centers of Nevada - Twain Office, Las Vegas
VA Greater Los Angeles Healthcare System, Los Angeles
University of California Los Angeles, Nuclear Medicine, Los Angeles
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Stanford Cancer Institute, Palo Alto
Swedish Cancer Institute Research, Seattle
University of Arizona Cancer Center, Tucson
Yale Cancer Center, New Haven
Dana Farber Cancer Institute, Boston
Beth Israel Deaconess Medical Center, Boston
Washington University School of Medicine, St Louis
Regional Cancer Care Associates, Central Jersey Division, East Brunswick
Oregon Health and Science University, Nuclear Medicine, Portland
Jules Bordet Institute, Brussels
Saint Luc University Hospital, Brussels
University Hospitals Leuven, Campus Gasthuisberg, Department of Nuclear Medicine, Leuven
Aalborg University Hospital, Oncology Department, Aalborg
Aarhus University Hospital, Department of Oncology, Aarhus
Rigshospitalet - University Hospital Copenhagen, Department of Oncology, Copenhagen
Bergonie Institute, Bordeaux
Center Jean Perrin, Clermont-Ferrand
Leon Berard Center, Lyon
Saint-Louis Hospital, Paris
Tenon Hospital, Paris
Institute Claudius Regaud, Toulouse Cancer Research Center, Toulouse
Gustave Roussy Oncology Institute, Villejuif
University Hospital Essen, Clinic for Nuclear Medicine, Essen
Hospital rechts der Isar, Department of Nuclear Medicine, Munich
University Hospital Muenster, Department of Nuclear Medicine, Münster
Rostock University Medical Center, Clinic and Polyclinic for Nuclear Medicine, Rostock
The Netherlands Cancer Institute, Amsterdam
St. Antonius Hospital, Nieuwegein
Radboud University Medical Center (Radboudumc), Nijmegen
UMC Utrecht, Utrecht
Sahlgrenska University Hospital, Department of Oncology, Gothenburg
Skane University Hospital - Barngatan, Clinical Trials Unit, Lund
Karolinska University Hospital, Stockholm
Norrlands University Hospital, Cancer Center, Umeå
Uppsala University Hospital, Department of Oncology, Uppsala
Bristol Hematology & Oncology Center, Bristol
Beatson West of Scotland Cancer Center, Glasgow
Royal Surrey County Hospital, Guildford
Guy's Hospital, London
Royal Free Hospital, London
St Bartholomew's Hospital, London
University College London Hospitals NHS Foundation Trust, London
University Hospital Southampton NHS Foundation Trust, Southampton
Institute of Cancer Research, Sutton
BC Cancer - Vancouver, Vancouver
London Health Sciences Centre, Division of Nuclear Medicine, London
Ottawa Hospital, Cancer Center, Ottawa
Sunnybrook Research Institute, Odette Cancer Center, Toronto
CHUM - University Hospital of Montreal, Montreal
Jewish General Hospital, Montreal
CHU of Quebec - Laval University, Québec
VA Caribbean Healthcare System, San Juan
Lead Sponsor
Endocyte
INDUSTRY